Given that in the current clinical routine the decision for targeted therapy, e.g., the use of anti-EGFR antibodies, is commonly based on the RAS-mutational status of a single tumor biopsy, inter-metastatic heterogeneity is likely to greatly influence the treatment outcomes of CRLM. Here, EGFR is linked to neoplasm.